• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Resolution of Macular Edema secondary to rituximab after intravitreal dexamethasone: A case report and a review of the literature
CONCLUSIONS AND IMPORTANCE: ME is a rare complication after Rituximab infusions and very few cases are reported in the literature. Usually, ME occurs a few weeks after systemic administration and is probably related to a local release of cytokines. It resolves with oral, subtenon or intravitreal steroids. Our case is the first showing that IDI is a safe and effective treatment in ME secondary to Rituximab. Rituximab is not required to be discontinued if treatment for ME is started.PMID:37644808 | DOI:10.1177/11206721231199120
Source: European Journal of Ophthalmology - August 30, 2023 Category: Opthalmology Authors: Martina Maceroni Angelo Maria Minnella Source Type: research

Intravitreal dexamethasone to manage post endothelial keratoplasty cystoid macular oedema refractory to topical therapy
Eur J Ophthalmol. 2023 Aug 22:11206721231189120. doi: 10.1177/11206721231189120. Online ahead of print.NO ABSTRACTPMID:37605631 | DOI:10.1177/11206721231189120
Source: European Journal of Ophthalmology - August 22, 2023 Category: Opthalmology Authors: Nuno Moura-Coelho Renato Papa-Vettorazzi Jos é L Güell Source Type: research

Changes in the uninjected contralateral eye after intravitreal brolucizumab for exudative age-related macular degeneration
CONCLUSIONS: Although contralateral retinal changes have been described for many other vascular endothelial growth factor inhibitors, there is little evidence for brolucizumab. We describe a repeated dose- and time-related effect on the uninjected eye in a case of nAMD.PMID:37424299 | DOI:10.1177/11206721231187429
Source: European Journal of Ophthalmology - July 10, 2023 Category: Opthalmology Authors: Paolo Mora Carlo Bellucci Lorenzo M Radice Francesca Manzotti Stefano Gandolfi Source Type: research

The efficacy of different anti-vascular endothelial growth factor agents, and dexamethasone implant therapy in patients with serous retinal detachment caused by Irvine-Gass syndrome
CONCLUSION: All intravitreal agents were effective in terms of visual results in the SRD patients; however, eyes treated with IVA and IVDI required fewer injections, as compared to the eyes treated with IVB and IVR. Furthermore, SRD entirely resolved in all eyes in the IVA group at the final follow-up visit.PMID:37408434 | DOI:10.1177/11206721231185909
Source: European Journal of Ophthalmology - July 6, 2023 Category: Opthalmology Authors: Bu ğra Karasu Enes Kesim Ali R ıza Cenk Celebi Source Type: research

A case of recurring acute exudative polymorphous vitelliform maculopathy successfully treated with intravitreal Ozurdex injection
CONCLUSION: Our case demonstrates clinical and imaging findings consistent with recurrence of AEPVM with CMO that has been successfully treated with Ozurdex®.PMID:37350018 | DOI:10.1177/11206721231178559
Source: European Journal of Ophthalmology - June 23, 2023 Category: Opthalmology Authors: Vaishali Lodhia Anthony G Robson Shaheeni Khoda Hanbin Lee Edward Hughes Source Type: research

Pages: 1  2  3  4  5  6  7